Fetal therapy for single gene disorders

Clinical Obstetrics and Gynecology

Volumn 48, Issue 4, 2005, Pages 885-896

  O'Brien, Barbara ^a   Bianchi, Diana W ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BILE ACID; BISPHOSPHONIC ACID DERIVATIVE; BLOOD CLOTTING FACTOR 9 COMPLEX; CHELATING AGENT; CYANOCOBALAMIN; GALACTOSYLCERAMIDASE; PAMIDRONIC ACID; RETROVIRUS VECTOR; SERINE; SIMVASTATIN;

3 PHOSPHOGLYCERATE DEHYDROGENASE DEFICIENCY; ALPHA THALASSEMIA; CHELATION; COMBINED IMMUNODEFICIENCY; CONGENITAL ADRENAL HYPERPLASIA; ENZYME DEFICIENCY; FETAL THERAPY; GENE THERAPY; GENETIC DISORDER; HEMOPHILIA B; HUMAN; IMMUNE DEFICIENCY; LYSOSOME STORAGE DISEASE; METHYLMALONIC ACIDEMIA; MUCOPOLYSACCHARIDOSIS; NONHUMAN; OSTEOGENESIS IMPERFECTA; REVIEW; SMITH LEMLI OPITZ SYNDROME; STEM CELL TRANSPLANTATION;

FEMALE; FETAL DISEASES; GENE THERAPY; GENETIC DISEASES, INBORN; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL DIAGNOSIS; STEM CELL TRANSPLANTATION;

EID: 29544439253     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.grf.0000184778.25663.ec     Document Type: Review

References (48)

1. Bianchi DW. Circulating fetal DNA: Its origin and diagnostic potential - a review. Placenta. 2004;25(Suppl A):S93-S101.
2. Lo YM. Fetal DNA in maternal plasma: application to non-invasive blood group genotyping of the fetus. Transfus Clin Biol. 2001;8:306-310.
3. Chiu RW, Lau TK, Cheung PT, et al. Noninvasive prenatal exclusion of congenital adrenal hyperplasia by maternal plasma analysis: a feasibility study. Clin Chem. 2002;48:778-780.
4. Saito H, Sekizawa A, Morimoto T, et al. Prenatal DNA diagnosis of a single-gene disorder from maternal plasma. Lancet. 2000;356:1170.
5. Gonzalez-Gonzalez MC, Garcia-Hoyas M, Trujillo MJ, et al. Prenatal detection of a cystic fibrosis mutation in fetal DNA from maternal plasma. Prenat Diagn. 2002;22:946-948.
6. Chiu RW, Lau TK, Leung TN, et al. Prenatal exclusion of beta thalassaemia major by examination of maternal plasma. Lancet. 2002;360:998-1000.
7. Amicucci P, Gennarelli M, Novelli G, et al. Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma. Clin Chem. 2000;46:301-302.
8. 12-responsive methylmalonic acidemia. N Engl J Med. 1975;293:313-317.
9. 12-responsive methylmalonic acidemia. J Pediatr. 1990;117:923-926.
10. Witsch-Baumgartner M, Loeffler J, Utermann G. Mutations in the human DHCR7 gene. Hum Mutat. 2001;17:172-182.
11. Irons MB, Elias ER, Salen G, et al. Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome. Lancet. 1993;341:1414.
12. Tint GS, Irons M, Elias ER, et al. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N Engl J Med. 1994;330:107-113.
13. Loeffler J, Utermann G, Witsch-Baumgartner M. Molecular prenatal diagnosis of Smith-Lemli-Opitz syndrome is reliable and efficient. Prenat Diagn. 2002;22:827-830.
14. Canick JA, Abuelo DN, Bradley LA, Tint GS. Maternal serum markers in two pregnancies affected with Smith-Lemli-Opitz syndrome. Prenat Diagn. 1997;17:187-189.
15. Canick JA, Abuelo DN, Bradley LA, et al. Maternal serum marker levels in two pregnancies affected with Smith-Lemli-Opitz syndrome. Prenat Diagn. 1997;17:187-189.
16. Schleifer RA, Bradley LA, Richards DS, et al. Pregnancy outcome for women with very low levels of maternal serum unconjugated estriol on second-trimester screening. Am J Obstet Gynecol. 1995;173:1152-1156.
17. Schoen E, Norem C, O'Keefe J, et al. Maternal serum unconjugated estriol as a predictor for Smith-Lemli-Opitz syndrome and other conditions. Obstet Gynecol. 2003;102:167-172.
18. Irons M, Elias ER, Abuelo D, et al. Treatment of Smith-Lemli-Opitz syndrome: results of a multicenter trial. Am J Med Genet. 1997;68:311-314.
19. Sikora DM, Ruggiero M, Petit-Kekel K, et al. Cholesterol supplementation does not improve developmental progress in Smith-Lemli-Opitz syndrome. J Pediatr. 2004;144:783-791.
20. Starck L, Lovgren-Sandblom A, Bjorkhem I. Simvastatin treatment in the SLO syndrome: a safe approach? Am J Med Genet. 2002;113:183-189.
21. Irons MB, Nores J, Stewart TL, et al. Antenatal therapy of Smith-Lemli-Opitz syndrome. Fetal Diagn Ther. 1999;14:133-137.
22. de Koning TJ, Klomp LW, van Oppen AC, et al. Prenatal and early postnatal treatment in 3-phosphoglycerate-dehydrogenase deficiency. Lancet. 2004;364:2221-2222.
23. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363:1377-1385.
24. Cole WG, Dalgleish R. Perinatal lethal osteogenesis imperfecta. J Med Genet. 1995;32:284-289.
25. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101-116.
26. Zeitlin L, Fassier F, Glorieux FH. Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop B. 2003;12:77-87.
27. Devogelaer JP, Malghem J, Maldague B, et al. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol. 1987;16:360-363.
28. Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947-952.
29. Horwitz EM, Prockop DJ, Fitzpatrick LA. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999;5:309-313.
30. Onyja JE, Clapp DW, Long H, et al. Trabecular and endosteal osteoprogenitor cells as targets for ex-vivo gene transfer. J Bone Miner Res. 1998;13:20-30.
31. Le Blanc K, Gotherstrom C, Ringden O, et al. Fetal mesenchymal stem cell engraftment in bone following in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation. 2005;79:1607-1614.
32. Buckley RH, Schiff SE, Schiff RI, et al. Haploidentical bone marrow stem cell transplantation in human severe combined immunodeficiency. Semin Hematol. 1993;30:92-101.
33. Flake AW, Roncarolo M, Puck JM, et al. Brief Report: treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow. N Engl J Med. 1996;335:1806-1810.
34. Westgren M, Ringden O, Bartmann P, et al. Prenatal T-cell reconstitution after in utero transplantation with fetal liver cells in a patient with X-linked severe combined immunodeficiency. Am J Obstet Gynecol. 2002;187:475-482.
35. Touraine JL, Raudrant D, Golfier F, et al. Reappraisal of in utero stem cell transplantation based on long-term results. Fetal Diagn Ther. 2004;19:305-312.
36. Chik KW, Shing MM, Li CK, et al. Treatment of hemoglobin Bart's hydrops with bone marrow transplantation. J Pediatr. 1998;132:1039-1042.
37. Zhou X, Ha SY, Chan GC, et al. Successful mismatched sibling cord blood transplant in Hb Bart's disease. Bone Marrow Transplant. 2001;18:105-107.
38. Thornley I, Lehmann L, Ferguson WS, et al. Homozygous alpha-thalassemia treated with intrauterine transfusions and postnatal hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;32:341-342.
39. Recombinant DNA Advisory Committee. Prenatal gene transfer: scientific, medical and ethical issues: a report of the Recombinant DNA Advisory Committee. Hum Gene Ther. 2000;11:1211-1229.
40. Waddington SN, Kennea NL, Buckley SM, et al. Fetal and neonatal gene therapy: benefits and pitfalls. Gene Ther. 2004;11(Suppl 1):S92-S97.
41. Riley RL. Neonatal immune response. In: Delves PJ, Roitt IM, eds. Encyclopedia of Immunology. London: Academic Press; 1998: 1818-1821.
42. Flake AW. Genetic therapies for the fetus. Clin Obstet Gynecol. 2002;45:684-696.
43. Pitt BR, Schwarz MA, Pilewski JM, et al. Retrovirus-mediated gene transfer in lungs of living fetal sheep. Gene Ther. 1995;2:334-350.
44. Porada CD, Tran N, Eglitis M, et al. In utero gene therapy: transfer and long-term expression of the bacterial neo® gene in sheep after direct injection of retroviral vectors into preimmune fetuses. Hum Gene Ther. 1998;9:1571-1585.
45. Themis M, Schneider H, Kiserud T, et al. Successful expression of beta-galactosidase and factor IX transgenes in fetal and neonatal sheep after ultrasound-guided percutaneous adenovirus vector administration into the umbilical vein. Gene Ther. 1999;6:1239-1248.
46. David A, Cook T, Waddington S, et al. Ultrasound-guided percutaneous delivery of adenoviral vectors encoding the beta galactosidase and human factor IX genes to early gestation fetal sheep in utero. Hum Gene Ther. 2003;14:353-364.
47. Waddington SN, Nivsarkar MS, Mistry AR, et al. Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. Blood. 2004;104:2714-2721.
48. Eto Y, Shen JS, Meng XL, et al. Treatment of lysosomal storage disorders: cell therapy and gene therapy. J Inherit Metab Dis. 2004;27:411-415.